ARK genomic analyst Ali Urman on the future of DNA sequencing

When it comes to uncovering breakthroughs in biotech, star stock picker Cathie Wood trusts Ali Urman’s eye. The genomics analyst at ARK Investment Management explains why the convergence of DNA sequencing, artificial intelligence and gene-editing/ gene therapy technologies hold the key to potentially curing disease.